Global Market Size, Forecast, and Trend Highlights Over 2025-2037
PEGylated Proteins Market size was over USD 2.5 billion in 2024 and is estimated to reach USD 9.1 billion by the end of 2037, expanding at a CAGR of 11.4% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of PEGylated proteins is assessed at USD 2.7 billion.
PEGylated protein therapies are increasingly achieving importance globally owing to the demand for PEGylation, incidences of chronic disorders, and the presence of the latest medication candidates. In addition, PEGylated compounds comprise benefits of long-lasting, minimum toxicity, reduced immunogenicity, and a surge in proteolytic protection. Besides, as per the September 2023 NLM article, the majority of PEGylated therapy solutions with 28 PEGylated proteins have received U.S. FDA approval, accounting for 93% of the PEGylated BLAs as well as 74% of approved PEGylated drugs, thereby enhancing the half-life of proteins. Therefore, all these factors are highly responsible for the growth and expansion of the market.
Furthermore, the amplification of the market hugely depends upon the implementation of polyethylene glycol (PEG) which improves stability and solubility and enhances pharmacokinetic properties. Therefore, there is a huge demand for PEG internationally due to its increasing export and import across nations. According to the 2023 OEC report, the global trade valuation of artificial and prepared waxes of PEG is USD 696 million with a product complexity of 1.2. In addition, the top exporter of the product is South Korea worth USD 179 million, and Turkey is the top importer at USD 116 million. Hence, the market is gaining more exposure internationally and catering to patient recovery, especially in developing nations.
Nationwide Artificial and Prepared PEG Waxes Export/Import
|
Countries |
Export |
Import |
|
Germany |
USD 164 million |
|
|
China |
USD 110 million |
|
|
Belgium |
USD 64.5 million |
|
|
United States |
USD 44.9 million |
USD 46.5 million |
|
India |
|
USD 78.1 million |
|
France |
|
USD 51.1 million |
|
Italy |
|
USD 49.1 million |
Source: OEC 2023
PEGylated Proteins Sector: Growth Drivers and Challenges
Growth Drivers
- Increased advancements in protein procedures: Foremost progressions in protein processes, which are expected to increase the extension of the global PEGylated proteins market, have made it possible to manufacture and produce constant and non-immunogenic pharmaceutical drugs. As per the August 2024 NLM article, through the PEGylated protein procedure, cancer cells develop resistance to almost 50% of anti-cancer medication which is a phenomenon denoted as multidrug confrontation. Therefore, for this purpose, it is essential to restrict the PEG 300 proportion to approximately 30% v/v, as concentrations higher than around 40% v/v can cause hemolytic effects.
- Development of novel therapies: This category of therapy focuses on improving results and treatment solutions for disorders, especially those with formerly incomplete or unproductive treatments, by pointing to precise mechanisms and pathways. For instance, in one of its 2025 articles, Biocon denoted its path-breaking developments in novel biologics that constitute internal research capabilities, toxicology studies, therapeutic modalities, and the unveiling of monoclonal antibodies such as EGFR and CD6. Thereby, all these factors cater to the evolution of standard novel therapies, highly driving the market.
Challenges
- Complex purification and isolation processes: The market faces a huge challenge owing to the presence of a complex procedural structure. This usually happens based on the given protein structure and its chosen persistence. In addition, both covalent and non-covalent connections happen among proteins of attention and passive PEG filaments. Also, the purification process of the PEGylated protein is an essential phase that is typically approved depending on molecular sizes, chromatography, and electrostatic interactions, thus constituting an overall intricate process.
- High cost of production: The complicated, elaborative, and exclusive nature of PEGylated proteins manufacturing constitutes a restraint for small and medium-sized organizations, thus causing a hindrance in the market. Besides, the huge expenditures can be driven based on the necessity for unconventional technology and severe quality control actions. This challenging factor is also associated with the aspect of drug development to aid numerous rare disorders, thus making it difficult for manufacturers to produce these proteins extensively.
PEGylated Proteins Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
11.4% |
|
Base Year Market Size (2024) |
USD 2.5 billion |
|
Forecast Year Market Size (2037) |
USD 9.1 billion |
|
Regional Scope |
|
PEGylated Proteins Segmentation
Product & Services (Consumables, Services)
Based on product & services, the consumables segment is expected to hold more than 69.2% PEGylated proteins market share by 2037. Factors such as ongoing research activities, product innovation, and the requirement to formulate drugs and drug delivery mechanisms are effectively contributing to the segment development. For instance, in the 2025 Enso Life Sciences article, the organization’s PEGylated protein ELISA kit caters to the quantitative identification of PEGylated molecules in serum, tissue, plasma, and other biological samples utilizing a modest ELISA arrangement. Additionally, the kit is suitable for therapeutic manufacturing applications, especially during medical formulation.
Application (Cancer, Autoimmune Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders)
Based on application, the cancer segment in the PEGylated proteins market is expected to register growth of over 18.5% till 2037. The increasing utilization of protein-based therapy solutions to diagnose cancer and combat its rising incidence is the ultimate factor for the segment’s growth. For instance, in June 2024, InduPro, Inc. declared a USD 85 million Series A investment co-led by The Column Group and Vida Ventures with the involvement of investors including MRL Ventures Fund and Emerson Collective, and Euclidean Capital. This initiated advancement to target cancer tissue on the basis of proximity and preclinical upgradation during the Phase I clinical trial.
Our in-depth analysis of the global market includes the following segments:
|
Product & Services |
|
|
Application |
|
|
Type |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPEGylated Proteins Industry - Regional Synopsis
North America Market Analysis
North America PEGylated proteins market is set to capture revenue share of around 40.8% by the end of 2037. The enhanced implementation of biologic pharmaceuticals suitable for the diagnosis and treatment of chronic disorders such as interferon, monoclonal antibodies, and erythropoietin is readily driving the market. In addition, expenditures from both the private sector and the government to initiate current initiatives are also uplifting market expansion in the region. Also, regulatory bodies naturally accept PEGylated entities that are non-immunogenic, non-antigenic, water-soluble, and non-toxic, thereby uplifting the market.
The market in the U.S. is gaining more traction owing to the presence and availability of polyethylene glycol through launches initiated by regional organizations. For instance, in March 2025, Glenmark Therapeutics Inc., USA announced the inauguration of polyethylene glycol 3350 for 17 grams in comparison to the active ingredient in MiraLAX2 powder for solution, 17 grams of Bayer HealthCare LLC. Besides, the presence of administrative organizations to approve such products is also a driving factor for the market in the region.
The PEGylated proteins market in Canada is effectively driven by the drug development urge that is possible through effective partnerships. For instance, in May 2023, AbCellera proclaimed a CA $701 million (USD 4.8 million) co-investment with the Government of Canada and British Columbia to shape the latest infrastructure and proficiencies. This further resulted in the evolution of state-of-the-art antibody-based medications and reinforced Canada’s leadership in drug development, manufacturing, and clinical research. Also, for the upcoming eight years, AbCellera planned to fund CA$401 million (USD 2.7 million) in the project, and the Governments of Canada and British Columbia will donate CA$225 million (USD 1.5 million) and CA$75 million (USD 5.2 million), respectively.
APAC Market Statistics
The PEGylated proteins market in the Asia Pacific is likely to witness the fastest growth during the forecast period. The region is still under development and is constantly connected to be engrossed in reduced costs of labor as well as investigation. Additionally, the low-cost-centered research in extremely inhabited countries such as China, India, and Japan is assessed to uplift the region’s progress. Also, the increasing elderly population as well as the enlarged necessity for proteins-based drugs for treatment is contributing to the market’s development in the region.
The market in India is attributed to expansion due to the presence of protein-based drugs. In addition, regional organizations are collaborating with international firms to develop cutting-edge immunotherapies which is also driving the market in the country. For instance, in December 2024, Mankind Pharma Limited partnered with Innovent Biologics to commercialize sintilimab, an advanced PD-1 immunotherapy, in the country. The purpose of this was to focus on life-threatening challenges in cancer treatment and ensure patient accessibility to ground-breaking therapeutic options in the country.
The PEGylated proteins market in China is gaining rapid exposure owing to the presence of governmental and administrative bodies to approve newly generated protein products. For instance, in January 2025, Astellas Pharma Inc. notified that China's National Medical Products Administration (NMPA) has approved VYLOY for the treatment of patients suffering from human epidermal growth factor receptor 2 (HER2)-negative gastric tumor. It is the first NMPA-approved monoclonal antibody to aim at gastric tumor cells that prompt the biomarker CLDN18.2, providing an extremely targeted method for cancer treatment, thereby driving market growth.
Companies Dominating the PEGylated Proteins Landscape
- Abcam plc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Thermo Fisher Scientific, Inc.
- Enzon Pharmaceuticals, Inc.
- Merck KGaA
- Celares GmbH
- Profacgen
- Creative PEGworks
- NOF America Corp.
- Aurigene Pharmaceutical Services Ltd.
- Laysan Bio, Inc.
- Evive Biotech
- VALANX Biotech
- Genexine
- KGbio
- Nektar Therapeutics
The PEGylated proteins market is perceiving the tendency of association for producing dominance, revenue, and relevance. Besides, organizational approaches including collaboration, acquisition, and partnership by key companies are aimed at strengthening their position. For instance, in November 2022, Evive Biotech entered into an agreement with Acrotech Biopharma to commercialize Ryzneuta in the USA. It is an innovative dimeric GCSF long-acting blended protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is under late-stage review currently by the US FDA for chemotherapy-induced neutropenia (CIN). Thereby, such association between organizations is expected to drive market evolution internationally.
Here's the list of some key players:
In the News
- In November 2024, Nektar Therapeutics stated its agreement to sell its Huntsville, Alabama manufacturing facility and reagent supply business to Ampersand Capital Partners. Ampersand decided to obtain Nektar's commercial-scale manufacturing facility and PEGylated reagent supply business for a total of USD 90 million.
- In June 2024, VALANX Biotech notified the successful in-vivo results in the company’s lead program VLX101 for the treatment of a wide range of autoimmune diseases. This potentially demonstrates VLX101, a novel Interleukin-2 conjugate, and the efficacy of VALANX proprietary technology platform and therapeutic approach.
- In October 2023, Genexine and KGbio acknowledged the first market sanction for novel long-acting erythropoietin, Efepoetin alfa, from The Indonesia Food and Drug Authority (BPOM) for the treatment of chronic kidney disease induced anemia.
Author Credits: Radhika Pawar
- Report ID: 7445
- Published Date: Apr 03, 2025
- Report Format: PDF, PPT
